A5051588487- Cancer Immunotherapy and Biomarkers
- Bladder and Urothelial Cancer Treatments
- Renal cell carcinoma treatment
- Immune Cell Function and Interaction
- Immune cells in cancer
- CAR-T cell therapy research
- Cancer Mechanisms and Therapy
- Epigenetics and DNA Methylation
- Ferroptosis and cancer prognosis
- Cancer Genomics and Diagnostics
- Immunotherapy and Immune Responses
- Lung Cancer Research Studies
- Asthma and respiratory diseases
- Renal and related cancers
- Urinary and Genital Oncology Studies
- Prostate Cancer Treatment and Research
- Cancer-related molecular mechanisms research
- Histone Deacetylase Inhibitors Research
- Neuroendocrine Tumor Research Advances
- RNA modifications and cancer
- Cancer, Lipids, and Metabolism
- Peptidase Inhibition and Analysis
- Retinal and Macular Surgery
- Lung Cancer Treatments and Mutations
- Multiple and Secondary Primary Cancers
The University of Texas MD Anderson Cancer Center
2016-2025
Vasan Eye Care Hospital
2017-2020
Pittsburg State University
2017
University of California, San Francisco
2006-2016
Gujarat Kidney Foundation
2015
Sun Yat-sen University
2014
Yale University
2014
Spanish Oncology Genitourinary Group
2014
Yale Cancer Center
2012
University of Pittsburgh Medical Center
2012
Enhancer of zeste homolog 2–mediated (EZH2-mediated) epigenetic regulation T cell differentiation and Treg function has been described previously; however, the role EZH2 in cell–mediated antitumor immunity, especially context immune checkpoint therapy, is not understood. Here, we showed that genetic depletion Tregs (FoxP3creEZH2fl/fl mice) leads to robust immunity. In addition, pharmacological inhibition human cells using CPI-1205 elicited phenotypic functional alterations enhanced cytotoxic...
CXCR2 in non-small cell lung cancer (NSCLC) has been studied mainly stromal cells and is known to increase tumor inflammation angiogenesis. Here, we examined the prognostic importance of NSCLC role its ligands cells. The effect expression on was using stable knockdown clones derived from a murine KRAS/p53-mutant adenocarcinoma line with high metastatic potential an orthotopic syngeneic mouse model vitro small-molecule antagonist (SB225002). protein analyzed 262 NSCLC. Gene profiles for...
A combination of ARID1A mutation and CXCL13 expression in baseline tumor tissues improves predictive capability for patients with mUCC receiving ICT.
The accumulation of immune-suppressive myeloid cells is a critical determinant resistance to anti–programmed death-1 (PD-1) therapy in advanced clear cell renal carcinoma (ccRCC). In preclinical models, the tyrosine kinase inhibitor sitravatinib enhanced responses anti–PD-1 by modulating cells. We conducted phase 1-2 trial choose an optimal dose combined with fixed nivolumab 42 immunotherapy-naïve patients ccRCC refractory prior antiangiogenic therapies. combination demonstrated no...
558 Background: Nivo/ipi is a standard of care first-line (1L) therapy for patients with metastatic clear-cell renal cell carcinoma (ccRCC) but its role in variant histology RCC (vhRCC) has not been fully defined. Methods: We report single-institution experience nivo/ipi to treat 55 vhRCC between Nov. 2017 and Feb. 2024 at MD Anderson Cancer Center. Tumor response was measured by blinded radiologists using RECIST v1.1. Descriptive statistics the Kaplan-Meier method were used. Results:...
Surgical removal of primary tumors reverses tumor-mediated immune suppression in pre-clinical models with metastatic disease. However, how cytoreductive surgery the setting modulates responses patients, especially context checkpoint therapy (ICT), is not understood. We report first prospective, pilot, non-comparative clinical trial (NCT02210117) to evaluate feasibility, benefits, and immunologic changes combining three different ICT-containing strategies or biopsy for patients clear cell...
Enfortumab vedotin is a Nectin-4 directed antibody-drug conjugate approved in metastatic urothelial carcinoma following progression on platinum-containing chemotherapy and immune checkpoint blockade. On-target dermatologic toxicity may occur from expression the skin. We highlight case of Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis enfortumab infusions that was ultimately fatal. The second describes an erythema multiforme-like rash with interface dermatitis related to enfortumab....
Adoptive transfer of tumor-reactive T cells (ACT) has led to modest clinical benefit in the treatment solid tumors. Failures with this therapy are primarily due inadequate infiltration and poor function adoptively transferred tumor microenvironment. To improve efficacy ACT, we combined ACT dual blockade CTLA-4 PD-1. Treatment anti-CTLA-4 plus anti-PD-1 compared monotherapy resulted durable antitumor responses, enhanced effector utilizing PMEL-1 transgenic (Tg+) CD8+ cells, improved survival....
630 Background: Adenocarcinomas of the urinary tract, including urachal (UA) and non-urachal (NUA) subtypes, are rare tumors. Triplet regimens combining gemcitabine, a taxane or 5-fluorouracil (5-FU)/leucovorin (L), cisplatin (P), have been developed. Methods: We retrospectively reviewed records patients receiving frontline (1L)GemFLP (Gemcitabine 200 mg/m 2 IV on days 1 5; 5-FU 1, 2, 3, 4, L 10mg/m P 20mg/m 5) in advanced UA NUA at MDACC between 2003 2023. Advanced disease is defined as...
Background Nivolumab plus ipilimumab (nivo/ipi) is a standard of care first-line (1 L) therapy for patients with metastatic clear-cell renal cell carcinoma (ccRCC), but its role in metastatic, non-ccRCC has not been fully defined. We report single-institution experience nivo/ipi non-ccRCC. Methods Between November 2017 and February 2024, 55 received at MD Anderson Cancer Center. The tumor response was assessed by blinded radiologists using RECIST v1.1. overall rate (ORR), progression-free...
545 Background: Over the last decade, immune checkpoint therapy (ICT) has become cornerstone of first-line treatment for mccRCC. Despite widespread use, there is heterogeneity in tumor response to ICT, and growing interest how host factors modulate microenvironment. Recent studies patients with mccRCC other malignancies suggest that ICT may be more effective higher body mass index (BMI). Since BMI an imperfect surrogate distinct compartments adipose tissue muscle, we investigated influence...
818 Background: MSI-high (MSI-H) and dMMR are three times more common in UTUC than bladder cancer. While these features enhance ICI sensitivity solid tumors, data on ICIs advanced with dMMR/MSI-H remain scarce. Methods: We retrospectively reviewed records of patients (pts) locally (LA) or metastatic treated at MD Anderson (2015-2024). Descriptive statistics the Kaplan-Meier method were used. Results: Twenty-four pts LA/unresectable (n=8) (n=16) disease (pembrolizumab, n=17; nivolumab, n=4;...